Overview

Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to see if lozenges containing a low dose of interferon-alpha can prevent and/or reduce the severity of colds and flu. Starting about 1 month before the expected start of the winter colds and flu season in Perth, Australia, healthy volunteers will allow a lozenge containing interferon, or a lozenge containing no medicine (a placebo), to dissolve in their mouth once a day for 16 weeks. Blood tests at the start and end of treatment will determine whether interferon was able to prevent infections with cold/flu viruses. Once a week, volunteers will complete a survey about their cold/flu symptoms, medications taken, days of work missed, etc. to see if interferon was able to make their winter colds and flu less severe.
Phase:
Phase 2
Details
Lead Sponsor:
Amarillo Biosciences, Inc.
Collaborator:
Department of Health, Western Australia
Treatments:
Interferon-alpha
Interferons